Stromal Cell Therapy to get Recognized as Emerging anthracycline-Induced Cardiomyopathy Treatment
Release Date: 19-Nov-2020
Patients suffering from anthracycline-induced cardiomyopathy are estimated to receive benefits from transendocardial administration of allogenic bone marrow-derived mesenchymal stromal cells. As per the clinical research activity with 31 cancer survivors with chronic anthracycline-induced cardiomyopathy, patients receiving transendocardial administration of allogenic bone marrow-derived mesenchymal stromal cells were observed to be having better quality of life as well as an inclining trend towards walking a distance of 6 min when compared with the placebo group. In the clinical research study, 97% of the patients received successful injections and all the enrolled patients received the therapy at the desired dose.
It was also observed that 6 minute walking of the enrolled patients increased after one year when compared with the placebo group. Also, the Minnesota Living with Heart Failure Questionnaire score declined from 46.6 at baseline to 21.2 in the group that received the dose when compared with placebo group where score decline from only 53.1 to 40.5. It was concluded by the researchers based on the clinical trial, that the study was safe and feasible in the patients suffering from anthracycline-induced cardiomyopathy. The future clinical trial for the same study will make the researchers provide more useful data with respect to the study.
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.